Determining Which DTC Patients May Benefit from Systemic Therapy
April 26th 2024Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
Read More
Diagnosing DTC: Clinical Workup and Molecular Testing
Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.
Read More
Overview on Differentiated Thyroid Cancer (DTC)
Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.
Read More